第24回あわじ感染と免疫国際フォーラム

○Shura Yarimizu¹, Takuya Hemmi^1,2,3, Nozomi Abe¹, Yuma Sato¹, Takao Hashiguchi¹ (1. Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyo to University (Japan), 2. Host Protection Dynamics Team, Center for Infectious Disease Education and Research, The University of Osaka (Japan), 3. Research Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan (Japan))

○FARZANEH VALANEZHAD^1,2,3, Jalal Alshaweesh^1,2, Shara Bakytbek^1,2,3, Alireza Valanezhad⁴, Kawsar Talaat⁵, Greg Matlashewski⁶, Sreenivas Gannavaram⁷, Hira Nakhasi⁷, Abhay Satoskar⁸, Shinjiro Hamano^1,2,3 (1. Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki, Japan (Japan), 2. Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan (Japan), 3. The Vaccine Research and Development Center, DEJIMA Infectious Disease Research Alliance (DIDA), Nagasaki University, Nagasaki, Japan (Japan), 4. Department of Dental and Biomedical Materials Science, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan (Japan), 5. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. (USA), 6. Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada (Canada), 7. Division of Emerging and Transfusion-Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993 US (USA), 8. Department of Pathology, The Ohio State University, Columbus, Ohio, US (USA))

○Kaidre Bendjama^1,2, Alexandru Odainic², Matheus Ferraz², Ioannis Vardaxis², Marius Gheorghe², Sebastian Kapell^1,2, Pierre Machart³, Raman Siarheyeu³, Yuki Tanaka⁴ (1. University of Nagasaki (Japan), 2. NEC Oncoimmunity (Norway), 3. NEC Laboratories Europe (Germany), 4. NEC Corporation (Japan))

○Malihe Naderi¹, Chrisan Bimo Prayuda^2,3, Jean Claude Balingit^1,4, Silvita Fitri Riswari^2,5, Gita Widya Pradini^2,5, Siti Rasnawati Mony², Dionisius Denis⁶, Diana S. Hansen⁷, Tedjo Sasmono⁸, Mya Myat Ngwe Tun^1,9,10,11, Kouichi Morita^1,9, Bachti Alisjahbana^2,5,12 (1. Department of Tropical Viral Vaccine Development, Institute of Tropical Medicine (Japan), 2. Research Center for Care and Control of Infectious Disease (RC3ID), Universitas Padjadjaran, Indonesia (Indonesia), 3. Faculty of Medicine, Universitas Islam Bandung, Indonesia. (Indonesia), 4. Department of Clinical Microbiology, Umeå universitet, Sweden (Sweden), 5. Faculty of Medicine, Universitas Padjadjaran, Indonesia. (Indonesia), 6. Exeins Health Initiative (EHI), Jakarta, Indonesia (Indonesia), 7. Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, Victoria, Australia (Australia), 8. Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Indonesia (Indonesia), 9. Department of Virology, Institute of Tropical Medicine, Nagasaki University. (Japan), 10. Center for Vaccines and Therapeutic Antibodies for Emerging Infectious Diseases, Shimane University (Japan), 11. DEJIMA Infectious Disease Research Alliance, Nagasaki University (Japan), 12. Department of Internal Medicine, Hasan Sadikin General Hospital, Indonesia. (Indonesia))

○Shara Bakytbek^1,2,3, Agnieszka Gromadka⁴, Wataru Kagaya^3,5, Huai Chuang^3,6, Yarob Ibraheem^1,2,3, Farzaneh Valanezhad^1,2,3, Ayako Hyuga^1,2,3, Marius Gheorghe⁴, Daiki Miura⁷, Alexandru Odainic⁴, Shin-Ichi Inoue^2,3,8, Shusaku Mizukami^3,9, Satoshi Kaneko^3,5, Kazuhide Onoguchi⁷, Sebastian Kapell^3,4,10, Kaïdre Bendjama^3,4, Osamu Kaneko^2,3,6, Shinjiro Hamano^1,2,3 (1. Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki (Japan), 2. Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki (Japan), 3. The Vaccine Research and Development Center, DEJIMA Infectious Disease Research Alliance (DIDA), Nagasaki University, Nagasaki (Japan), 4. NEC Oncoimmunity AS, Oslo (Norway), 5. Department of Eco-epidemiology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan), 6. Department of Protozoology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan), 7. AI Drug Development Division, NEC Corporation, Tokyo (Japan), 8. Department of Molecular Microbiology and Immunology, Division of Immunology, Nagasaki University, Nagasaki (Japan), 9. Department of Immune Regulations, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan), 10. Department of Vaccine Informatics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan))

○Micheal Teron Pillay¹, Shara Bakytbek², Anton Kratz¹, Kaidre Bendjama^1,3, Sebastian Kapell^1,3 (1. Nagasaki University, Institute of Tropical Medicine, Department of Vaccine Informatics (Japan), 2. Nagasaki University, Institute of Tropical Medicine, Department of Parasitology (Japan), 3. NEC Oncoimmunity AS, Oslo (Norway))